Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 20/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.85 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.79 |
| ▸ | TSPO | P30536 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22996148 | 1.00 | P2RY14 (1.00) | P2RY14OPRD1KCNH2SIGMAR1TMEM97 | |
| SCHEMBL29691860 | 0.94 | P2RY14 (1.00) | P2RY14OPRD1KCNH2TMEM97TSPO | |
| SCHEMBL21264015 | 0.92 | P2RY14 (1.00) | P2RY14OPRD1KCNH2SIGMAR1TMEM97 | |
| SCHEMBL29691902 | 0.91 | P2RY14 (1.00) | P2RY14OPRD1KCNH2TMEM97TSPO | |
| SCHEMBL30608312 | 0.90 | P2RY14 (0.89) | P2RY14OPRD1KCNH2TMEM97TSPO | |
| SCHEMBL29691896 | 0.88 | P2RY14 (0.86) | P2RY14OPRD1KCNH2TMEM97TSPO | |
| SCHEMBL29691872 | 0.88 | P2RY14 (1.00) | P2RY14OPRD1KCNH2SIGMAR1TMEM97 | |
| SCHEMBL29691826 | 0.86 | P2RY14 (1.00) | P2RY14OPRD1KCNH2TMEM97TSPO | |
| SCHEMBL29691843 | 0.85 | P2RY14 (1.00) | P2RY14OPRD1KCNH2TMEM97TSPO | |
| SCHEMBL29691816 | 0.85 | P2RY14 (0.83) | P2RY14OPRD1KCNH2TMEM97TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584736-B2 | Heterocyclic P2Y14 receptor antagonists | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584736-B2 | Heterocyclic P2Y14 receptor antagonists | P2RY14, P2RY1, P2RY13 | P2RY14 1/4885OPRD1 241/4885KCNH2 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.